Genfit's NASH drug fails a closely-watched PhIII showdown, adding one more setback to a plagued field
Genfit’s bid to make R&D history with a storybook turnaround came to a crashing halt on Monday as the French biotech acknowledged that its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
